
Consilium publication out today! Check ⬇️
It may be that failure to count competitors stampeding towards your de-risked target is now the single biggest reason drug R&D programs fail in Phase 2 & 3. "Commercial" termination overtakes "efficacy" circa 2019: nature.com/articles/d41573-0… Recent oncology example (TIGIT herding): bmjoncology.bmj.com/content/…

























